These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 26231191

  • 1. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
    Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E.
    Clin J Am Soc Nephrol; 2015 Oct 07; 10(10):1749-56. PubMed ID: 26231191
    [Abstract] [Full Text] [Related]

  • 2. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.
    Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT.
    Am J Kidney Dis; 2019 Mar 07; 73(3):354-362. PubMed ID: 30578153
    [Abstract] [Full Text] [Related]

  • 3. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT.
    Am J Kidney Dis; 2015 Jun 07; 65(6):833-41. PubMed ID: 25600953
    [Abstract] [Full Text] [Related]

  • 4. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL, Spithoven EM, Casteleijn NF, Dam WA, van den Born J, Tonnis WF, Gaillard CAJM, Meijer E, DIPAK Consortium.
    BMC Nephrol; 2018 Dec 19; 19(1):368. PubMed ID: 30567514
    [Abstract] [Full Text] [Related]

  • 5. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):803-811. PubMed ID: 26912543
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang JJ, Czerwiec FS.
    Am J Kidney Dis; 2011 May 06; 57(5):692-9. PubMed ID: 21333426
    [Abstract] [Full Text] [Related]

  • 7. Effect of Vasopressin on the Hypothalamic-Pituitary-Adrenal Axis in ADPKD Patients during V2 Receptor Antagonism.
    Heida JE, Minović I, van Faassen M, Kema IP, Boertien WE, Bakker SJL, van Beek AP, Gansevoort RT.
    Am J Nephrol; 2020 May 06; 51(11):861-870. PubMed ID: 33147589
    [Abstract] [Full Text] [Related]

  • 8. The association of urinary epidermal growth factors with ADPKD disease severity and progression.
    Harskamp LR, Perez-Gomez MV, Heida JE, Engels GE, van Goor H, van den Heuvel MC, Streets AJ, Ong ACM, Ortiz A, Gansevoort RT, DIPAK Consortium.
    Nephrol Dial Transplant; 2023 Sep 29; 38(10):2266-2275. PubMed ID: 36914219
    [Abstract] [Full Text] [Related]

  • 9. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb 29; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

  • 10. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.
    Al Therwani S, Malmberg MES, Rosenbaek JB, Bech JN, Pedersen EB.
    BMC Nephrol; 2017 Aug 15; 18(1):268. PubMed ID: 28810844
    [Abstract] [Full Text] [Related]

  • 11. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
    Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.
    J Am Soc Nephrol; 2017 May 15; 28(5):1592-1602. PubMed ID: 27920153
    [Abstract] [Full Text] [Related]

  • 12. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
    Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS.
    Kidney Int; 2011 Aug 15; 80(3):295-301. PubMed ID: 21544064
    [Abstract] [Full Text] [Related]

  • 13. Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients.
    Geertsema P, Koorevaar IW, Ipema KJR, Kramers BJ, Casteleijn NF, Gansevoort RT, Meijer E.
    Nephrol Dial Transplant; 2024 Mar 27; 39(4):707-716. PubMed ID: 37804179
    [Abstract] [Full Text] [Related]

  • 14. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators.
    N Engl J Med; 2017 Nov 16; 377(20):1930-1942. PubMed ID: 29105594
    [Abstract] [Full Text] [Related]

  • 15. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators.
    N Engl J Med; 2012 Dec 20; 367(25):2407-18. PubMed ID: 23121377
    [Abstract] [Full Text] [Related]

  • 16. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
    Bargagli M, Dhayat NA, Anderegg M, Semmo M, Huynh-Do U, Vogt B, Ferraro PM, Fuster DG.
    Clin J Am Soc Nephrol; 2020 Jul 01; 15(7):1007-1014. PubMed ID: 32527945
    [Abstract] [Full Text] [Related]

  • 17. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators.
    Clin J Am Soc Nephrol; 2011 Oct 01; 6(10):2499-507. PubMed ID: 21903984
    [Abstract] [Full Text] [Related]

  • 18. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
    Boertien WE, Meijer E, de Jong PE, Bakker SJ, Czerwiec FS, Struck J, Oberdhan D, Shoaf SE, Krasa HB, Gansevoort RT.
    Kidney Int; 2013 Dec 01; 84(6):1278-86. PubMed ID: 23903369
    [Abstract] [Full Text] [Related]

  • 19. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
    Grantham JJ, Chapman AB, Blais J, Czerwiec FS, Devuyst O, Gansevoort RT, Higashihara E, Krasa H, Zhou W, Ouyang J, Perrone RD, Torres VE, TEMPO 3:4 Investigators.
    Nephrol Dial Transplant; 2017 Jun 01; 32(6):969-975. PubMed ID: 27190355
    [Abstract] [Full Text] [Related]

  • 20. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
    Casteleijn NF, Blais JD, Chapman AB, Czerwiec FS, Devuyst O, Higashihara E, Leliveld AM, Ouyang J, Perrone RD, Torres VE, Gansevoort RT, TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3:4 Trial Investigators.
    Am J Kidney Dis; 2017 Feb 01; 69(2):210-219. PubMed ID: 27856088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.